Total Payments
$4,436
2024 Payments
$4,216
Companies
7
Transactions
10
Medicare Patients
1,212
Medicare Billing
$97,271
Payment Breakdown by Category
Other$4,000 (90.2%)
Food & Beverage$422.47 (9.5%)
Education$13.19 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $4,000 | 1 | 90.2% |
| Food and Beverage | $422.47 | 8 | 9.5% |
| Education | $13.19 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UROGEN PHARMA, INC. | $4,203 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $77.94 | 1 | $0 (2018) |
| Astellas Pharma Global Development | $58.82 | 1 | $0 (2022) |
| Janssen Biotech, Inc. | $45.56 | 1 | $0 (2019) |
| Abbott Laboratories | $22.88 | 1 | $0 (2017) |
| PFIZER INC. | $14.00 | 1 | $0 (2018) |
| Ferring Pharmaceuticals Inc. | $13.19 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,216 | 5 | UROGEN PHARMA, INC. ($4,203) |
| 2022 | $58.82 | 1 | Astellas Pharma Global Development ($58.82) |
| 2019 | $45.56 | 1 | Janssen Biotech, Inc. ($45.56) |
| 2018 | $91.94 | 2 | AstraZeneca Pharmaceuticals LP ($77.94) |
| 2017 | $22.88 | 1 | Abbott Laboratories ($22.88) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Honoraria | Cash or cash equivalent | $4,000.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/05/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $151.00 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/05/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $35.70 | General |
| Category: UROTHELIAL CANCER | ||||||
| 08/10/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: UROTHELIAL CANCER | ||||||
| 02/21/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Education | In-kind items and services | $13.19 | General |
| Category: ONCOLOGY | ||||||
| 02/16/2022 | Astellas Pharma Global Development | Xtandi (Drug) | Food and Beverage | In-kind items and services | $58.82 | General |
| Category: Oncology | ||||||
| 12/06/2019 | Janssen Biotech, Inc. | Erleada (Drug) | Food and Beverage | In-kind items and services | $45.56 | General |
| Category: Oncology | ||||||
| 11/29/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $77.94 | General |
| Category: Oncology | ||||||
| 11/29/2018 | PFIZER INC. | SUTENT (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 06/06/2017 | Abbott Laboratories | Vysis UroVysion (Device), Vysis UroVysion, Vysis UroVysion | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Molecular Diagnostics | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 273 | 371 | $74,147 | $20,399 |
| 2022 | 3 | 239 | 322 | $65,651 | $17,717 |
| 2021 | 4 | 314 | 437 | $84,877 | $23,101 |
| 2020 | 10 | 386 | 536 | $214,587 | $36,054 |
Total Patients
1,212
Total Services
1,666
Medicare Billing
$97,271
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 111 | $20,202 | $7,563 | 37.4% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 64 | 97 | $30,943 | $4,964 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 64 | 76 | $9,860 | $3,348 | 34.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 46 | $8,372 | $3,249 | 38.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 19 | $2,460 | $855.83 | 34.8% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 13 | 22 | $2,310 | $420.42 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 77 | 101 | $18,382 | $7,014 | 38.2% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2022 | 53 | 85 | $27,115 | $4,448 | 16.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 72 | 80 | $10,315 | $3,024 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 35 | $7,054 | $2,245 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 18 | 21 | $2,785 | $986.18 | 35.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 78 | 103 | $20,084 | $6,786 | 33.8% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2021 | 63 | 114 | $36,366 | $6,483 | 17.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 90 | 115 | $14,685 | $5,445 | 37.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 32 | 43 | $5,685 | $2,175 | 38.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 32 | 41 | $7,462 | $2,100 | 28.1% |
| 51741 | Electronic assessment of bladder emptying | Office | 2021 | 19 | 21 | $595.00 | $111.70 | 18.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 102 | 132 | $24,633 | $7,509 | 30.5% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2020 | 75 | 119 | $37,625 | $6,878 | 18.3% |
| 52240 | Destruction and/or removal of large growths of the bladder using an endoscope | Facility | 2020 | 13 | 18 | $25,560 | $5,684 | 22.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 45 | 57 | $10,374 | $3,127 | 30.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 36 | $13,320 | $2,891 | 21.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 39 | 47 | $7,238 | $2,759 | 38.1% |
| 52332 | Insertion of stent in urinary duct (ureter) using an endoscope | Facility | 2020 | 15 | 34 | $61,010 | $2,580 | 4.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 24 | 26 | $6,344 | $1,945 | 30.7% |
About Dr. Edward Messing, MD
Dr. Edward Messing, MD is a Urology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174562425.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Messing, MD has received a total of $4,436 in payments from pharmaceutical and medical device companies, with $4,216 received in 2024. These payments were reported across 10 transactions from 7 companies. The most common payment nature is "Honoraria" ($4,000).
As a Medicare-enrolled provider, Messing has provided services to 1,212 Medicare beneficiaries, totaling 1,666 services with total Medicare billing of $97,271. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Rochester, NY
- Active Since 06/05/2006
- Last Updated 07/03/2023
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1174562425
Products in Payments
- JELMYTO (Drug) $4,203
- IMFINZI (Drug) $77.94
- Xtandi (Drug) $58.82
- Erleada (Drug) $45.56
- Vysis UroVysion (Device) $22.88
- SUTENT (Drug) $14.00
- ADSTILADRIN (Biological) $13.19
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Rochester
Tobias Kohler, Md, MD
Urology — Payments: $176,600
Urology $176,600
Dr. Jonathan Warner, M.d, M.D
Urology — Payments: $149,347
Urology $149,347
Sevann Helo, M.d, M.D
Urology — Payments: $96,211
Urology $96,211
Ahmed Ghazi, Md, MD
Urology — Payments: $57,583
Urology $57,583
Stephen Boorjian, M.d, M.D
Urology — Payments: $47,998
Urology $47,998
Mr. John Valvo, Md, MD
Urology — Payments: $28,953
Urology $28,953